REGENXBIO Inc. (NASDAQ: RGNX) reported fourth‑quarter 2025 results that included $30.34 million in revenue, up 43% from $21.2 million in Q4 2024, and a net loss of $67.1 million, or $1.30 per share. The loss widened from the $61.9 million net loss ($1.20 per share) reported in Q3 2025, indicating a continued decline in profitability as the company invests heavily in its pipeline. The earnings miss was driven by a $1.15 million shortfall in revenue relative to the consensus estimate of $31.49 million and an EPS miss of $0.32 versus the consensus range of –$0.98 to –$0.91.
The full‑year 2025 results showed $170.4 million in revenue, more than double the $83.3 million reported in 2024, while the annual net loss expanded to $193.9 million, or $3.76 per share. Research and development expenses rose to $228.3 million, reflecting continued investment in the RGX‑202, RGX‑121 and ABBV‑RGX‑314 programs. Cash, cash equivalents and marketable securities stood at $240.9 million as of December 31 2025, a balance that management says will fund operations into early 2027 if no additional milestone payments or non‑dilutive financing are received.
Management reiterated that the cash runway is based on current operating plans and does not include potential milestone payments. The company expects a $100 million milestone payment from AbbVie in Q2 2026, which could extend the runway further. "We are rapidly advancing our late‑stage pipeline of gene therapies to treat rare and retinal diseases with significant unmet need, with multiple near‑term catalysts in 2026," said President and CEO Curran Simpson. "We will drive continued momentum across our programs – powered by our fully in‑house, end‑to‑end capabilities, commercial‑ready manufacturing, and global partners. We remain focused on executing on our mission to deliver meaningful new medicines to patients in need through the curative potential of gene therapy."
Investors reacted negatively to the earnings release, largely because the company missed both revenue and EPS estimates. The EPS miss of $0.32 versus the consensus range of –$0.98 to –$0.91 and the revenue miss of $1.15 million versus the $31.49 million estimate underscored concerns about the company’s near‑term financial performance. Headwinds include FDA clinical holds on RGX‑111 and RGX‑121 and a complete response letter for RGX‑121, while tailwinds come from the advancement of RGX‑202 and ABBV‑RGX‑314 programs.
The results highlight a company that is heavily investing in R&D, which has driven a widening net loss despite a strong year‑over‑year revenue increase. The cash balance provides a buffer, but the company’s ability to sustain operations will depend on the timing of milestone payments and the resolution of regulatory challenges. The earnings miss signals that execution is slower than analysts expected, but the continued pipeline progress and potential milestone inflows suggest that the company’s long‑term prospects remain anchored in its gene‑therapy platform.
revised_sentiment_rating:-2}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.